NFE2L2 and non-small cell lung carcinoma: In conclusion, high bTMB and PD-L1 expression ≥ 1% were associated with longer PFS in patients with stage III NSCLC undergoing CRT and consolidative durvalumab, while ctDNA-detected pathogenic mutations in STK11, KEAP1, or NFE2L2 were linked to shorter PFS.